Bookmark and Share

Markey Research Directory

Search for Investigators

Heidi L. Weiss, PhD

Cancer Center Member
Markey Research Programs:
    Drug Discovery, Delivery and Translational Therapeutics

Associate Director, Shared Resources and Director, Biostatistics Shared Resource Facility

Professor

Department of Surgery
College of Medicine

Research Focus

Design and analysis of early phase clinical trials focusing on Bayesian design and interim monitoring. Statistical analysis of transgenic, xenograft and chemically induced mouse models of cancer.

Contact Information

800 Rose Street
CC448 Roach Building
University of Kentucky
Lexington, Kentucky 40536
859-323-0577
heidi.weiss@uky.edu

Key Publications

  1. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S and Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat 129:819-27, 2011.
  2. Weiss HL, Urban DA, Grizzle WE, Cronin KA, Freedman LS, Kelloff GJ, Lieberman R. Bayesian Monitoring of a phase II chemoprevention trial in high risk cohorts for prostate cancer. Urology 57(4A):220-223, 2001.

Five Most Recent Publications (via PubMed, based on researcher's ID and University of Kentucky)

1.  Zaytseva YY, Elliott VA, Rychahou P, Mustain WC, Kim JT, Valentino J, Gao T, O'Connor KL, Neltner JM, Lee EY, Weiss HL, Evers BM.
Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer.
Carcinogenesis. 2014 Jun;35(6):1341-51.
2.  Hollis CP, Weiss HL, Evers BM, Gemeinhart RA, Li T.
In vivo investigation of hybrid Paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics.
Pharm Res. 2014 Jun;31(6):1450-9.
3.  Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T.
Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery.
J Control Release. 2013 Nov;172(1):12-21.
4.  Wang Q, Zhou Y, Rychahou P, Liu C, Weiss HL, Evers BM.
NFAT5 represses canonical Wnt signaling via inhibition of β-catenin acetylation and participates in regulating intestinal cell differentiation.
Cell Death Dis. 2013;4:e671.
5.  Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, Townsend CM, Liu C, Evers BM.
Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
Carcinogenesis. 2013 May;34(5):953-61.